Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 119

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 119
---
 Kaken, or to any of their respective properties or assets, by the execution and delivery of, and performance under, the Divestiture Agreement and the other transaction documents, and 
 of the completion of the Divestiture and the other transactions contemplated by the Divestiture Agreement and the other transaction documents;                                                                                                          |

| • |     | subject to certain exceptions, the absence of any consent of any governmental authority required in connection                                                      
 with the execution and delivery of, and performance under, the Divestiture Agreement and the other transaction documents, and of the completion of the Divestiture; |

| • |     | the absence of pending or threatened legal proceedings and orders relating to Kaken; |

| • |     | Kaken’s ownership of shares of Aadi’s capital stock; |

| • |     | brokers’ fees and expenses; |

| • |     | the absence of any vote or consent by holders of Kaken capital stock required for the approval of the Divestiture 
 Agreement or the Divestiture;                                                                                     |

| • |     | Kaken’s financial capability to make all payments contemplated by the Divestiture Agreement, pay all fees                                                        
 and expenses required to be paid at completion of the Divestiture and the resources and capabilities to perform its obligations under the Divestiture Agreement; |

| • |     | the absence of stockholder and management arrangements; and |

| • |     | Kaken’s investment intent and status as an “accredited investor” as defined in Regulation D 
 promulgated under the Securities Act.                                                       |

Under the Divestiture Agreement, Aadi and Aadi Sub acknowledge that Kaken and its subsidiaries have not made any representations or warranties other than in connection with the Divestiture Agreement or the Divestiture and expressly disclaim reliance on any representation, warranty or other information regarding Kaken, other than those expressly set forth in the Divestiture Agreement. Certain of the representations and warranties contained in the Divestiture Agreement will survive for designated periods of time after the completion of the Divestiture as further described in the section of this proxy statement captioned “ The Divestiture Agreement—Indemnification.” Conduct of Business Pending the Divestiture Other than as expressly contemplated by the Divestiture Agreement, set forth in the confidential disclosure letter to the Divestiture Agreement, as required by applicable law or approved by Kaken (which approval, under the terms of the Divestiture Agreement, may not be unreasonably withheld, conditioned